IPD Share Price Performance
AU$0.019
-0.03 (-60.42%)
72.9% undervalued intrinsic discount
AU$0.07
Fair Value
Price AU$0.019
AnalystLowTarget AU$0.07
AnalystConsensusTarget AU$0.098
AnalystHighTarget AU$0.13
Fair ValueAU$0.07
Share Pricen/a
ImpediMed Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
IPD Community Narratives
AN
Fair Value AU$0.07 72.9% undervalued intrinsic discount
Heart Failure Opportunity May Struggle Against Reimbursement And Sales Risks Yet Eventually Gain Traction
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value AU$0.098 80.6% undervalued intrinsic discount
Heart Failure And Lymphedema Trends Will Drive Durable Long Term Demand
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value AU$0.13 85.5% undervalued intrinsic discount
Lymphedema And Heart Failure Reimbursement Expansion Will Transform This Undervalued Medical Device Story
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Lymphedema And Heart Failure Reimbursement Expansion Will Transform This Undervalued Medical Device Story
Catalysts About ImpediMed ImpediMed develops and commercializes SOZO, a bioimpedance spectroscopy platform used by clinicians to measure fluid and body composition across multiple indications. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AU$0.13
85.5% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
39.46% p.a.
Profit Margin
80.19%
Future PE
12.28x
Price in 2029
AU$0.17
Heart Failure And Lymphedema Trends Will Drive Durable Long Term Demand
Catalysts About ImpediMed ImpediMed develops and commercializes SOZO, a bioimpedance spectroscopy platform used to detect and manage lymphedema, heart failure and body composition in clinical and wellness settings. What are the underlying business or industry changes driving this perspective?Read more
35
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AU$0.098
80.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
32.87% p.a.
Profit Margin
1.45%
Future PE
584.77x
Price in 2028
AU$0.12
Heart Failure Opportunity May Struggle Against Reimbursement And Sales Risks Yet Eventually Gain Traction
Catalysts About ImpediMed ImpediMed develops and commercializes SOZO, a bioimpedance spectroscopy platform used to monitor fluid status and body composition across lymphedema, heart failure and related conditions. What are the underlying business or industry changes driving this perspective?Read more
27
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AU$0.07
72.9% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
36.26% p.a.
Profit Margin
0.096%
Future PE
58.77x
Price in 2028
AU$0
Trending Discussion
Recently Updated Narratives
AN
Lymphedema And Heart Failure Reimbursement Expansion Will Transform This Undervalued Medical Device Story
Fair Value: AU$0.13 85.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Heart Failure And Lymphedema Trends Will Drive Durable Long Term Demand
Fair Value: AU$0.098 80.6% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Heart Failure Opportunity May Struggle Against Reimbursement And Sales Risks Yet Eventually Gain Traction
Fair Value: AU$0.07 72.9% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
ImpediMed Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.011
- 86.25%
- -182.62%
- 67.3%
About IPD
- Founded
- 1999
- Employees
- 77
- CEO
- WebsiteView website
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue composition; L-Dex analysis for lymphedema; BodyComp Analysis, a point-of-care body composition analysis; and HF-Dex analysis for point-of-care heart failure fluid assessment. It also provides SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. ImpediMed Limited was incorporated in 1999 and is headquartered in Carlsbad, California with additional office in Lindfield, Australia.
